IL272561A - Antibodies with modified FC variants to increase half-life in the blood - Google Patents
Antibodies with modified FC variants to increase half-life in the bloodInfo
- Publication number
- IL272561A IL272561A IL272561A IL27256120A IL272561A IL 272561 A IL272561 A IL 272561A IL 272561 A IL272561 A IL 272561A IL 27256120 A IL27256120 A IL 27256120A IL 272561 A IL272561 A IL 272561A
- Authority
- IL
- Israel
- Prior art keywords
- variants
- half life
- serum half
- engineered antibody
- enhanced serum
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544622P | 2017-08-11 | 2017-08-11 | |
| PCT/US2018/046398 WO2019033087A1 (en) | 2017-08-11 | 2018-08-11 | MODIFIED FC ANTIBODY VARIANTS FOR ENHANCED SERIAL HALF LIFE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL272561A true IL272561A (en) | 2020-03-31 |
Family
ID=65272701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272561A IL272561A (en) | 2017-08-11 | 2020-02-09 | Antibodies with modified FC variants to increase half-life in the blood |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11059892B2 (OSRAM) |
| EP (1) | EP3665195A4 (OSRAM) |
| JP (3) | JP7191087B2 (OSRAM) |
| KR (1) | KR102867311B1 (OSRAM) |
| CN (1) | CN111032688A (OSRAM) |
| AU (1) | AU2018314257B2 (OSRAM) |
| CA (1) | CA3072099A1 (OSRAM) |
| IL (1) | IL272561A (OSRAM) |
| WO (1) | WO2019033087A1 (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3152009A1 (en) * | 2019-08-22 | 2021-02-25 | Cidara Therapeutics, Inc. | Variant fc domains and uses thereof |
| CN115515975A (zh) * | 2020-05-21 | 2022-12-23 | 兹杜斯生命科学有限公司 | Fc变体及其制备 |
| US20220144923A1 (en) * | 2020-11-11 | 2022-05-12 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
| CA3215049A1 (en) | 2021-04-10 | 2022-10-13 | Baiteng ZHAO | Folr1 binding agents, conjugates thereof and methods of using the same |
| JP7742892B2 (ja) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | 抗ｃｄ７０抗体、そのコンジュゲートおよびこれを使用する方法 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| WO2023108115A1 (en) * | 2021-12-10 | 2023-06-15 | Board Of Regents, The University Of Texas System | Ph-selective antibody fc domains |
| WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
| WO2024044477A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| WO2024243423A1 (en) | 2023-05-24 | 2024-11-28 | Mozart Therapeutics, Inc. | Cd8-specific binding proteins and methods of using the same |
| WO2025014774A1 (en) | 2023-07-07 | 2025-01-16 | Viridian Therapeutics, Inc. | Methods of treating active and chronic thyroid eye disease |
| TW202535954A (zh) | 2023-09-26 | 2025-09-16 | 丹麥商珍美寶股份有限公司 | Ｐｔｋ７結合劑、其共軛物及使用彼等之方法 |
| WO2025117639A1 (en) | 2023-11-27 | 2025-06-05 | Profoundbio Us Co. | Antibodies and methods for ptk7 detection |
| US20250296992A1 (en) | 2024-01-10 | 2025-09-25 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025171006A1 (en) * | 2024-02-06 | 2025-08-14 | Paragon Therapeutics, Inc. | Il-23 binding protein compositions and methods of use |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| WO2025222129A2 (en) | 2024-04-19 | 2025-10-23 | Mozart Therapeutics, Inc. | Engineered cytokines and targeted cytokine delivery |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7094571B2 (en) | 2000-10-27 | 2006-08-22 | The Board Of Regents Of The University Of Texas System | Combinatorial protein library screening by periplasmic expression |
| US7419783B2 (en) | 2001-11-05 | 2008-09-02 | Research Development Foundation | Engineering of leader peptides for the secretion of recombinant proteins in bacteria |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20030219870A1 (en) | 2002-03-23 | 2003-11-27 | George Georgiou | Secretion of proteins with multiple disulfide bonds in bacteria and uses thereof |
| US7611866B2 (en) | 2002-07-15 | 2009-11-03 | Board Of Regents, The University Of Texas System | Selection of bacterial inner-membrane anchor polypeptides |
| US9051373B2 (en) * | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| EP2314618A3 (en) * | 2004-11-12 | 2011-10-19 | Xencor Inc. | Fc variants with altered binding to FcRn |
| AU2006204791A1 (en) | 2005-01-12 | 2006-07-20 | Xencor, Inc | Antibodies and Fc fusion proteins with altered immunogenicity |
| EP2134847B1 (en) | 2007-03-07 | 2015-06-24 | Aarhus Universitet | Pig model for atherosclerosis |
| WO2008137475A2 (en) | 2007-05-01 | 2008-11-13 | Research Development Foundation | Immunoglobulin fc libraries |
| EP2448972A4 (en) | 2009-06-30 | 2012-11-28 | Res Dev Foundation | IMMUNOGLOBULIN FC POLYPEPTIDES |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| GB201112429D0 (en) * | 2011-07-19 | 2011-08-31 | Glaxo Group Ltd | Antigen-binding proteins with increased FcRn binding |
| TW201817745A (zh) * | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| US20150050269A1 (en) | 2011-09-30 | 2015-02-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities |
| CN104010659A (zh) | 2011-12-19 | 2014-08-27 | 洛克菲勒大学 | 非唾液酸化的抗炎多肽 |
| ES2856272T3 (es) * | 2012-05-30 | 2021-09-27 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígenos para eliminar antígenos agregados |
| JP6832709B2 (ja) * | 2014-05-16 | 2021-02-24 | メディミューン，エルエルシー | 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子 |
| JP6034332B2 (ja) | 2014-05-30 | 2016-11-30 | トヨタ自動車株式会社 | 組換え微生物及び当該組換え微生物を用いた物質製造方法 |
| BR112017006178A2 (pt) * | 2014-11-06 | 2018-05-02 | F. Hoffmann-La Roche Ag | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos |
| UY37829A (es) * | 2017-08-03 | 2019-01-31 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
-
2018
- 2018-08-11 CN CN201880051999.9A patent/CN111032688A/zh active Pending
- 2018-08-11 CA CA3072099A patent/CA3072099A1/en active Pending
- 2018-08-11 AU AU2018314257A patent/AU2018314257B2/en active Active
- 2018-08-11 US US16/101,421 patent/US11059892B2/en active Active
- 2018-08-11 KR KR1020207004453A patent/KR102867311B1/ko active Active
- 2018-08-11 JP JP2020507074A patent/JP7191087B2/ja active Active
- 2018-08-11 EP EP18844094.5A patent/EP3665195A4/en active Pending
- 2018-08-11 WO PCT/US2018/046398 patent/WO2019033087A1/en not_active Ceased
-
2020
- 2020-02-09 IL IL272561A patent/IL272561A/en unknown
-
2021
- 2021-06-14 US US17/346,648 patent/US11958904B2/en active Active
-
2022
- 2022-08-09 JP JP2022126967A patent/JP7583767B2/ja active Active
-
2024
- 2024-04-05 US US18/628,078 patent/US20240270852A1/en active Pending
- 2024-11-01 JP JP2024193182A patent/JP2025013474A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3072099A1 (en) | 2019-02-14 |
| JP7191087B2 (ja) | 2022-12-16 |
| US11958904B2 (en) | 2024-04-16 |
| AU2018314257B2 (en) | 2025-03-27 |
| EP3665195A1 (en) | 2020-06-17 |
| JP2022145845A (ja) | 2022-10-04 |
| JP7583767B2 (ja) | 2024-11-14 |
| KR20200035972A (ko) | 2020-04-06 |
| KR102867311B1 (ko) | 2025-10-01 |
| CN111032688A (zh) | 2020-04-17 |
| AU2018314257A1 (en) | 2020-02-13 |
| JP2025013474A (ja) | 2025-01-24 |
| US11059892B2 (en) | 2021-07-13 |
| US20210347891A1 (en) | 2021-11-11 |
| US20240270852A1 (en) | 2024-08-15 |
| JP2020530296A (ja) | 2020-10-22 |
| EP3665195A4 (en) | 2021-05-19 |
| WO2019033087A1 (en) | 2019-02-14 |
| US20190048078A1 (en) | 2019-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272561A (en) | Antibodies with modified FC variants to increase half-life in the blood | |
| IL256848A (en) | Antibody molecules that bind cd45 | |
| IL278941A (en) | DPRS antibodies that originate in the human body | |
| SG11201709573YA (en) | Specific modification of antibody with igg-binding peptide | |
| IL247277A0 (en) | Monoclonal antibodies against Ebola | |
| GB201817172D0 (en) | Antibody | |
| EP3103811A4 (en) | Anti-tissue factor monoclonal antibody | |
| DK3166970T3 (da) | FORBEDREDE Aß-PROTOFIBRILBINDENDE ANTISTOFFER | |
| IL266857A (en) | You will notice antibodies | |
| IL273529A (en) | Anti-PACAP antibody | |
| GB201811368D0 (en) | Antibody | |
| EP3515949A4 (en) | NEW ANTI-PCSK9 ANTIBODIES | |
| IL250404A0 (en) | A new anti-igbeta antibody of human origin | |
| IL260083A (en) | Antibody against myl9 | |
| SMT202100313T1 (it) | Composti 1-ciano-pirrolidinici come inibitori di usp30 | |
| EP3515950A4 (en) | NEW ANTI-PCSK9 ANTIBODIES | |
| ZA201802019B (en) | Humanized anti psa (5a10) antibodies | |
| ZA202001830B (en) | Antibody variants | |
| IL272951A (en) | antibody variants | |
| HK40032866A (en) | Engineered antibody fc variants for enhanced serum half life | |
| GB201511196D0 (en) | Monoclonal antibodies | |
| SG11202105718TA (en) | Modified antibodies | |
| GB201908009D0 (en) | Anti-PCSK9 antibodies | |
| GB201817354D0 (en) | Engineered FC | |
| GB201813597D0 (en) | Antibody |